This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Universite De Tours, Centre Hospitalier Régional Universitaire De Tours, Centre National De La Recherche Scientifique. Active years: 2021-2026.
Company Filing History:
2 out of 19 
1 out of 5 
1 out of 5,383 
Years Active: 2021-2026
Title: Olivier Herault: Innovator in Hemopathy Prognosis
Introduction
Olivier Herault is a notable inventor based in La Tremblaye, France. He has made significant contributions to the field of medical technology, particularly in the prognosis of chemotherapy responses for individuals suffering from chronic myeloid leukemia. His innovative approach has the potential to improve treatment outcomes for patients.
Latest Patents
Olivier Herault holds a patent for a method titled "Hemopathy prognosis method." This invention relates to an in vitro method for predicting the response to chemotherapy in patients with chronic myeloid leukemia. The method involves measuring the expression level of specific gene subgroups, followed by a comparison step, and ultimately determining a score S. If S is less than 1, the individual has more than a 40% chance of responding to chemotherapy. Conversely, if S is greater than or equal to 1, the individual has less than a 40% chance of responding to the treatment.
Career Highlights
Throughout his career, Olivier Herault has worked with esteemed institutions such as Université de Tours and the Centre National de la Recherche Scientifique. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to significant advancements in medical research.
Collaborations
Olivier Herault has collaborated with fellow researcher Olivier Sire, enhancing the scope and impact of their work in the medical field.
Conclusion
Olivier Herault's innovative contributions to hemopathy prognosis demonstrate his commitment to improving patient care in oncology. His work continues to influence the medical community and offers hope for better treatment strategies for chronic myeloid leukemia patients.